Anteris Technologies Global Corp. (NASDAQ:AVR) Financings
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Closed: US$200M raised · US$5.75 a share · Barclays +3 Dealers: Barclays (co-lead), Wells Fargo Securities (co-lead), Cantor (co-lead), Barrenjoey Markets Pty Limited Use of proceeds: To support the global pivotal PARADIGM trial and advance toward global commercialization of the DurAVR Transcatheter Heart Valve | Jan 22, 2026 |
| Strategic investment of common stock Closed: US$90M raised · Wells Fargo Securities Dealers: Wells Fargo Securities (lead) Buyers: Medtronic plc (up to $90.0 million of shares, 16.0% to 19.99% of shares outstanding after the Offering); Medtronic, plc ($90 million strategic investment) Use of proceeds: To support the global pivotal PARADIGM trial and advance toward global commercialization of the DurAVR Transcatheter Heart Valve | Jan 22, 2026 |